Login to Your Account

Clinic Roundup

Wednesday, April 6, 2011
Neurocrine Biosciences Inc., of San Diego, completed dosing and preliminary assessment of its initial cohort of patients in an open-label, Phase IIa trial of NBI-98854 for tardive dyskinesia. NBI-98854 is a vesicular monoamine transporter 2 inhibitor (VMAT2). After 12 days of treatment with the drug, test subjects showed improvement in the abnormal hyperkinetic movements caused by tardive dyskinesia.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription